

14461 U.S. PTO

UTILITY
PATENT APPLICATION
TRANSMITTAL(Only for new non-provisional
applications under 37 CFR 1.53(b))

Title of Invention

In Vitro and In Vivo Models for Screening
Compounds to Prevent Glucocorticoid-Induced
Bone Destruction

Named Inventor(s)

Stavros C. Manolagas, Robert L. Jilka, Robert S.
Weinstein, and Teresita Bellido

Attorney Docket

06572.105006 CON

Express Mail Label No.

EV330779150US

APPLICATION ELEMENTS

ADDRESS TO: Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

ACCOMPANYING APPLICATION PARTS

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status. See 37 CFR 1.27.
3. ☒ Specification, Claims,
and Abstract Total Pages 53
4. ☒ Drawings Total Sheets 5
5. Oath or Declaration Total Pages
- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17
completed)
- (i) ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior
application, see 37 CFR 1.63(d)(2)
and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76.
7. ☐ CD-ROM or CD-R in duplicate, large table or
Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence
Submission (if applicable, all necessary)
- a. ☐ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
- ii. ☐ paper
- c. ☐ Statement verifying identity of above
copies

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee)
☐ Power of Attorney by
assignee
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)
PTO-1449
☐ Copies of IDS
- Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
16. ☒ Assignee: Board of Trustees of the University of
Arkansas

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/413,958

Prior application information: Examiner: Patrick J. Nolan

Group/Art Unit: 1644

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. CORRESPONDENCE ADDRESS:

Sherry M. Knowles
KING & SPALDING LLP
45th Floor
191 Peachtree Street, N.E.
Atlanta, Georgia 30303By: Sherry Knowles Reg. No. 33,052
Date: December 8, 2003
Telephone: 404.572.3541
Facsimile: 404.572.5145
Customer No. 20786

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Unassigned
Continuation of 09/413,958 Group Art Unit: 1644
Filed: October 7, 1999 Examiner: Nolan, Patrick J.
Inventor(s) : Stavros Manolagas, *et al.*
Title : In Vitro and In Vivo Models for Screening Compounds to
Prevent Glucocorticoid-Induced Bone Destruction
T.C./A.U. : Not yet assigned
Examiner : Not yet assigned
Docket No. : 06572.105006
Customer No.: 20786

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 CFR § 1.53(b)


Sir:

This is a request by Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, and Teresita Bellido for filing a Continuation Application under 37 C.F.R. § 1.53(b) of pending prior application U.S. Serial No. 09/413,958, filed on October 7, 1999, currently pending.

Enclosed is a copy of the prior application U.S.S.N. 09/413,958 as originally filed on October 7, 1999. The application includes fifty-three pages of Specification and five pages Formal Drawings. I hereby verify that the attached papers are a true copy of what is shown in my records to be the above-identified prior application.

Stavros C. Manolagas, Robert L. Jilka, Robert S. Weinstein, and Teresita Bellido have assigned their interest in the application to the Board of Trustees of the University of Arkansas, on October 14, 2003. Copies of the assignments are enclosed. Also enclosed are copies of the executed Declarations for Patent Application and Powers of Attorney and a Preliminary Amendment.

Respectfully submitted,


Sherry M. Knowles
Reg. No. 33,052

Date: December 8, 2003
Express Mail Label EV330779150US

King & Spalding LLP
191 Peachtree Street
Atlanta, Georgia 30303
404-572-3541 (telephone)
404-572-5145 (facsimile)
Attorney Docket No. ANA 1001 CON

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10
FOR UTILITY PATENT APPLICATION FILING

I hereby certify that this Request for filing a Continuation Application, Transmittal of Utility Patent Application, Utility Patent Application, and Fee Transmittal, along with any documents referred to as attached therein are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addresses" services under 37 CFR 1.10, Mailing Label Number EV330779150US addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.



Stephanie D. Adams

Date: December 8, 2003